81250-33-1

Usage

Uses

Used in Pharmaceutical Industry:
6-Amino-1,3-dipropyl-5-nitrosouracil is used as a chemical intermediate for the synthesis of xanthine derivatives, which are important in the development of pharmaceutical compounds. These xanthine derivatives have potential applications in the treatment of various diseases and conditions, such as asthma, allergies, and certain neurological disorders.
Used in Chemical Research:
In the field of chemical research, 6-Amino-1,3-dipropyl-5-nitrosouracil is utilized as a starting material for the synthesis of novel xanthine-based compounds. This allows researchers to explore the potential therapeutic properties of these newly synthesized compounds and contribute to the advancement of medicinal chemistry.
Used in Drug Development:
6-Amino-1,3-dipropyl-5-nitrosouracil plays a crucial role in drug development, as it is involved in the synthesis of xanthine derivatives that may possess therapeutic properties. By using this intermediate, researchers can create new drug candidates that can be further optimized and tested for their efficacy and safety in treating various medical conditions.

InChI:InChI=1S/C10H16N4O3/c1-3-5-13-8(11)7(12-17)9(15)14(6-4-2)10(13)16/h3-6,11H2,1-2H3

Upstream product

• 41862-14-0 6-amino-1,3-dipropyluracil 
• 623-95-0 1,3-dipropylurea 
• 859732-95-9 2-cyano-N-propyl-N-(propylcarbamoyl)acetamide 

Downstream Products

• 127252-57-7 6-Amino-5-{[1-phenyl-meth-(E)-ylidene]-amino}-1,3-dipropyl-1H-pyrimidine-2,4-dione 
• 132940-68-2 N-(6-Amino-2,4-dioxo-1,3-dipropyl-1,2,3,4-tetrahydro-pyrimidin-5-yl)-3-phenyl-propionamide 
• 127252-60-2 6-Amino-5-{[1-(4-hydroxy-phenyl)-meth-(E)-ylidene]-amino}-1,3-dipropyl-1H-pyrimidine-2,4-dione 
• 132940-49-9 4-{[(E)-6-Amino-2,4-dioxo-1,3-dipropyl-1,2,3,4-tetrahydro-pyrimidin-5-ylimino]-methyl}-benzonitrile 
• 132940-71-7 (E)-N-(6-Amino-2,4-dioxo-1,3-dipropyl-1,2,3,4-tetrahydro-pyrimidin-5-yl)-3-phenyl-acrylamide 
• 132940-39-7 8-Phenethyl-1,3-dipropyl-3,7-dihydro-purine-2,6-dione 
• 85872-53-3 1,3-dipropyl-8-phenylxanthine 
• 132940-42-2 (E)-1,3-dipropyl-8-styrylxanthine 
• 94781-76-7 8-(4-hydroxyphenyl)-1,3-dipropyl-1,3,7-trihydropurine-2,6-dione 
• 116545-90-5 1,3-dipropyl-8-(4-cyanophenyl)xanthine 
• 340021-17-2 3-(4-(2,6-dioxo-1,3-dipropyl-2,3,6,9-tetrahydro-1H-purin-8-yl)bicyclo[2.2.2]octan-1-yl)propanoic acid 
• 137685-69-9 3,7-dihydro-8-[(+/-)-phenylpropyl]-1,3-dipropyl-1H-purine-2,6-dione 

Relevant academic research and scientific papers

Development and Application of Subtype-Selective Fluorescent Antagonists for the Study of the Human Adenosine A1Receptor in Living Cells

The adenosine A1 receptor (A1AR) is a G-protein-coupled receptor (GPCR) that provides important therapeutic opportunities for a number of conditions including congestive heart failure, tachycardia, and neuropathic pain. The development of A1AR-selective fluorescent ligands will enhance our understanding of the subcellular mechanisms underlying A1AR pharmacology facilitating the development of more efficacious and selective therapies. Herein, we report the design, synthesis, and application of a novel series of A1AR-selective fluorescent probes based on 8-functionalized bicyclo[2.2.2]octylxanthine and 3-functionalized 8-(adamant-1-yl) xanthine scaffolds. These fluorescent conjugates allowed quantification of kinetic and equilibrium ligand binding parameters using NanoBRET and visualization of specific receptor distribution patterns in living cells by confocal imaging and total internal reflection fluorescence (TIRF) microscopy. As such, the novel A1AR-selective fluorescent antagonists described herein can be applied in conjunction with a series of fluorescence-based techniques to foster understanding of A1AR molecular pharmacology and signaling in living cells.

Bronchospasmolytic activity and adenosine receptor binding of some newer 1,3-dipropyl-8-phenyl substituted xanthine derivatives

The aldehyde derivatives of 1,3-dipropyl xanthines as described in this paper, constitutes a new series of selective adenosine ligands displaying bronchospasmolytic activity. The effect of substitution at third- and fourth-position of 8-phenyl xanthine ha

Synthesis of novel 3,7-dihydro-purine-2,6-Dione derivatives

Forty-six novel 3,7-dihydro-purine-2,6-dione derivatives (substituted xanthines) with great structural diversity were synthesized for biological activity screening. Three series of substituted xanthine analogs have been prepared in moderate to excellent y

Adenosine A2A receptor-antagonist/dopamine D2 receptor-agonist bivalent ligands as pharmacological tools to detect A 2A-D2 receptor heteromers

Adenosine A2A (A2AR) and dopamine D2 (D2R) receptors mediate the antagonism between adenosinergic and dopaminergic transmission in striatopallidal GABAergic neurons and are pharmacological targets for the treatment of Parkinson's disease.Here, a family of heterobivalent ligands containing a D2R agonist and an A 2AR antagonist linked through a spacer of variable size was designed and synthesized to study A2AR-D2R heteromers. Bivalent ligands with shorter linkers bound to D2R or A2AR with higher affinity than the corresponding monovalent controls in membranes from brain striatum and from cells coexpressing both receptors. In contrast, no differences in affinity of bivalent versus monovalent ligands were detected in experiments using membranes from cells expressing only one receptor. These findings indicate the existence of A2AR-D2R heteromers and of a simultaneous interaction of heterobivalent ligands with both receptors. The cooperative effect derived from the simultaneous interaction suggests the occurrence of A2AR-D2R heteromers in cotransfected cells and in brain striatum. The dopamine/adenosine bivalent action could constitute a novel concept in Parkinson's disease pharmacotherapy.

Synthesis, biological and modeling studies of 1,3-di-n-propyl-2,4-dioxo-6- methyl-8-(substituted) 1,2,3,4-tetrahydro [1,2,4]-triazolo [3,4-f]-purines as adenosine receptor antagonists

A new series of potential adenosine receptor antagonists with a [1,2,4]-triazolo-[3,4-f]-purine structure bearing at the 1 and 3 position n-propyl groups have been synthesized, and their affinities at the four human adenosine receptor subtypes (A1/s

NOVEL XANTHINES HAVING ADENOSINE A1-RECEPTOR ANTAGONIST PROPERTIES

The subject invention provides 1,3-dipropylxanthines that have an ester function at the 8-position also have potent and specific A1AdoR antagonist properties.

XANTHINE DERIVATIVES AS ADENOSINE A1 RECEPTOR ANTAGONISTS

A method of attenuating a cognitive deficit in a patient in need thereof comprising administering to the patient a xanthine derivative.

8-substituted xanthines as selective adenosine receptor agents

Xanthine derivatives having general structure (I) including the (R) and (S) enantiomers and racemic mixtures thereof, and the pharmaceutically acceptable salts thereof, wherein R 1 and R 2 are each independently (C 1 -C 4)lower alkyl or (C 2 -C 4)lower al

1,3,8-Trisubstituted xanthines. Effect of substitution pattern upon adenosine receptor A1/A2 affinity

A series of 11,8-substituted xanthines having three different substitution patterns on the 1- and 3-positions was prepared.These compounds were assessed for

Selective adenosine receptor agents

Xanthine derivative which act selectively at adenosine receptors and which act in general as adenosine antagonists are disclosed. From in vitro studies it is known that specific physiological effects can be distinguished as a result of this selectively and that adenosine receptor activity in vitro correlates with adenosine receptor activity in vivo.Pharmaceutical preparations of the subject compounds can be prepared on the basis of the selective binding activity of the compounds disclosed herein which will enhance certain physiological effects while minimizing others, such as decreasing blood pressure without decreasing heart rate.